Switzerland· 60117003
Cleviprex, emulsion pour perfusion
A clevidipine product containing clevidipinum, registered in Switzerland by Chiesi SA and dispensed under Swissmedic category B. The same ATC class is registered in 8 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Clevidipine is registered in 8 of 19 countries.
Countries holding a registration under ATC C08CA16 (clevidipine), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 4 of them publish a price we can compare per daily dose
Clevidipine · ATC C08CA16
8 / 19 countries
- Belgiumprice
- Canada
- Franceprice
- Germany
- Netherlands
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- clevidipinum
- Manufacturer
- Chiesi SA
- Country
- Switzerland (CH)
- ATC code
- C08CA16
- ATC class
- Clevidipine
- Defined daily dose
- 0.12 g, P
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
92 interactions on record for clevidipine.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clevidipine · interactions on record
92 records
- 5 severe
- 85 moderate
- 1 minor
Most severe, free to view
- DolasetronA04AA04severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
- SiponimodL04AA42severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Clevidipine in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCleviprexChiesi USA, Inc.
- BelgiumCleviprex 0.5 mg/mlChiesi
- GermanyCleviprexChiesi Gmbh
- SpainCLEVIPREX 0,5MG/ML EMULSION INYECTABLEChiesi España S.A.U.
- FranceCLEVIPREX 0,5 mg/ml, émulsion injectableCHIESI
- United KingdomCleviprex 25mg/50ml emulsion for infusion vialsChiesi Ltd
- NetherlandsCleviprex 0,5 mg/ml, emulsie voor injectieChiesi Pharmaceuticals B.V.
- SwedenCleviprex 0,5 mg/ml Injektionsvätska, emulsionChiesi Farmaceutici S.p.A.
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- Austria · Cleviprex
- Belgium · Cleviprex
- Germany · Cleviprex
- Spain · Cleviprex
- France · Cleviprex
- Italy · Cleviprex
- Luxembourg · Cleviprex
- Netherlands · Cleviprex
- Sweden · Cleviprex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/771a3c33-7e5f-47de-b2cd-1ff89691d5b4 GET /v1/drugs/771a3c33-7e5f-47de-b2cd-1ff89691d5b4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about clevidipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.